Amedisys (NASDAQ:AMED) had its target price hoisted by Robert W. Baird from $105.00 to $120.00 in a research note published on Thursday morning. They currently have a neutral rating on the health services provider’s stock.
AMED has been the subject of a number of other research reports. Royal Bank of Canada boosted their price objective on shares of Amedisys to $115.00 and gave the company an outperform rating in a report on Friday, August 3rd. SunTrust Banks boosted their price objective on shares of Amedisys to $130.00 and gave the company a buy rating in a report on Thursday. Cantor Fitzgerald initiated coverage on shares of Amedisys in a report on Thursday, September 13th. They issued a neutral rating and a $117.00 price objective for the company. Bank of America raised shares of Amedisys from a neutral rating to a buy rating and boosted their price objective for the company from $88.00 to $97.00 in a report on Tuesday, July 3rd. Finally, ValuEngine raised shares of Amedisys from a buy rating to a strong-buy rating in a report on Monday, July 30th. Five equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. Amedisys has a consensus rating of Buy and an average price target of $95.38.
NASDAQ AMED opened at $109.28 on Thursday. The company has a quick ratio of 1.21, a current ratio of 1.21 and a debt-to-equity ratio of 0.30. The stock has a market capitalization of $3.98 billion, a price-to-earnings ratio of 49.45, a price-to-earnings-growth ratio of 1.89 and a beta of 1.00. Amedisys has a 12-month low of $45.60 and a 12-month high of $127.38.
Amedisys (NASDAQ:AMED) last posted its quarterly earnings data on Tuesday, July 31st. The health services provider reported $1.00 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.78 by $0.22. The firm had revenue of $411.60 million during the quarter, compared to the consensus estimate of $403.62 million. Amedisys had a net margin of 4.46% and a return on equity of 20.11%. During the same quarter in the previous year, the firm posted $0.62 EPS. On average, research analysts forecast that Amedisys will post 3.41 EPS for the current fiscal year.
In other news, insider David B. Pearce sold 398 shares of the business’s stock in a transaction that occurred on Wednesday, July 25th. The shares were sold at an average price of $94.18, for a total value of $37,483.64. Following the completion of the transaction, the insider now directly owns 12,216 shares in the company, valued at approximately $1,150,502.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 2.60% of the stock is currently owned by insiders.
Large investors have recently modified their holdings of the company. Glenmede Trust Co. NA raised its position in shares of Amedisys by 4.3% in the 2nd quarter. Glenmede Trust Co. NA now owns 71,559 shares of the health services provider’s stock valued at $6,116,000 after buying an additional 2,959 shares in the last quarter. Moneta Group Investment Advisors LLC acquired a new position in shares of Amedisys in the 2nd quarter valued at approximately $181,000. Algert Global LLC acquired a new position in shares of Amedisys in the 2nd quarter valued at approximately $1,208,000. Piedmont Investment Advisors LLC raised its position in shares of Amedisys by 9.3% in the 2nd quarter. Piedmont Investment Advisors LLC now owns 6,668 shares of the health services provider’s stock valued at $570,000 after buying an additional 567 shares in the last quarter. Finally, Cubist Systematic Strategies LLC increased its position in Amedisys by 1,086.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 2,372 shares of the health services provider’s stock worth $203,000 after purchasing an additional 2,172 shares in the last quarter. Institutional investors own 93.31% of the company’s stock.
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.
Read More: Bond
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.